Market Price

19.35 

-1.47 -7.1%

as of Feb 03 '23

52 Week Range:

16.85 126.50


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 1.64
1.71
1.91
1.92
2.22
2.18
2.52
2.60
2.95
3.41
3.85
growth rate 4.3% 11.7% 0.5% 15.6% -1.8% 15.6% 3.2% 13.5% 15.6% 12.9%
Earnings BIT 31,493.00
34,492.00
46,619.00
48,432.00
48,967.00
47,248.00
52,483.00
54,476.00
59,341.00
growth rate 9.5% 35.2% 3.9% 1.1% -3.5% 11.1% 3.8% 8.9%
Avg.PE 23.61
26.81
22.61
15.08
16.07
16.08
16.08
16.08
16.08
growth rate 13.6% -15.7% -33.3% 6.6% 0.1% 0.0% 0.0% 0.0%
ROA 27.12
32.88
37.03
35.93
41.29
40.06
38.15
36.25
32.96
31.15
28.14
growth rate 21.2% 12.6% -3.0% 14.9% -3.0% -4.8% -5.0% -9.1% -5.5% -9.7%
ROE 45.95
54.90
60.54
63.92
79.90
82.23
80.20
76.00
71.19
69.70
71.24
growth rate 19.5% 10.3% 5.6% 25.0% 2.9% -2.5% -5.2% -6.3% -2.1% 2.2%
ROIC 45.02
54.18
60.02
63.09
78.31
81.11
78.65
74.44
66.55
62.14
55.89
growth rate 20.4% 10.8% 5.1% 24.1% 3.6% -3.0% -5.4% -10.6% -6.6% -10.1%
Cur. Ratio 1.91
1.86
1.74
1.37
1.35
1.26
1.28
1.09
1.06
0.94
0.86
growth rate -2.6% -6.5% -21.3% -1.5% -6.7% 1.6% -14.8% -2.8% -11.3% -8.5%
Quick Ratio 1.45
1.37
1.22
0.99
1.03
0.95
0.90
0.79
0.76
0.64
0.65
growth rate -5.5% -11.0% -18.9% 4.0% -7.8% -5.3% -12.2% -3.8% -15.8% 1.6%
Leverage 1.73
1.62
1.65
1.91
1.95
2.15
2.05
2.14
2.18
2.29
2.75
growth rate -6.4% 1.9% 15.8% 2.1% 10.3% -4.7% 4.4% 1.9% 5.1% 20.1%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 11,115.00
12,027.00
15,174.00
19,001.00
21,613.00
24,197.00
23,551.00
26,889.00
29,152.00
32,184.00
46,799.00
growth rate 8.2% 26.2% 25.2% 13.8% 12.0% -2.7% 14.2% 8.4% 10.4% 45.4%
Acct.Payable 3,291.00
3,859.00
4,092.00
4,950.00
4,927.00
6,011.00
5,833.00
6,756.00
6,358.00
5,717.00
8,870.00
growth rate 17.3% 6.0% 21.0% -0.5% 22.0% -3.0% 15.8% -5.9% -10.1% 55.2%
Cur.Assets 39,591.00
40,163.00
42,058.00
46,293.00
55,140.00
59,766.00
60,080.00
59,067.00
62,456.00
65,809.00
85,595.00
growth rate 1.4% 4.7% 10.1% 19.1% 8.4% 0.5% -1.7% 5.7% 5.4% 30.1%
Total Assets 64,698.00
65,669.00
70,337.00
77,062.00
91,799.00
97,539.00
102,355.00
110,769.00
125,612.00
144,922.00
194,508.00
growth rate 1.5% 7.1% 9.6% 19.1% 6.3% 4.9% 8.2% 13.4% 15.4% 34.2%
Cash 13,408.00
11,553.00
10,728.00
14,396.00
16,923.00
18,690.00
18,852.00
15,638.00
15,475.00
12,757.00
10,720.00
growth rate -13.8% -7.1% 34.2% 17.6% 10.4% 0.9% -17.1% -1.0% -17.6% -16.0%
Inventory 9,433.00
9,543.00
9,552.00
11,357.00
12,758.00
14,341.00
15,373.00
16,336.00
17,641.00
18,536.00
19,621.00
growth rate 1.2% 0.1% 18.9% 12.3% 12.4% 7.2% 6.3% 8.0% 5.1% 5.9%
Cur.Liabilities 20,779.00
21,638.00
24,225.00
33,689.00
40,873.00
47,436.00
47,056.00
54,164.00
58,983.00
70,273.00
99,516.00
growth rate 4.1% 12.0% 39.1% 21.3% 16.1% -0.8% 15.1% 8.9% 19.1% 41.6%
Liabilities 27,250.00
25,037.00
27,768.00
36,768.00
44,830.00
52,270.00
52,540.00
58,930.00
68,019.00
81,597.00
123,762.00
growth rate -8.1% 10.9% 32.4% 21.9% 16.6% 0.5% 12.2% 15.4% 20.0% 51.7%
LT Debt 502.00
9,654.00
growth rate 34.4%
Equity 42,569.00
40,294.00
46,969.00
45,269.00
49,815.00
51,839.00
57,593.00
63,325.00
70,746.00
growth rate -5.3% 16.6% -3.6% 10.0% 4.1% 11.1% 10.0% 11.7%
Common Shares 2,851.00
2,758.00
2,694.00
2,630.00
2,578.00
2,535.00
2,478.00
490.00
480.00
470.00
462.00
growth rate -3.3% -2.3% -2.4% -2.0% -1.7% -2.3% -80.2% -2.0% -2.1% -1.7%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 3,073.00
3,372.00
3,238.00
3,990.00
5,224.00
7,068.00
7,626.00
9,636.00
8,932.00
5,825.00
6,335.00
growth rate 9.7% -4.0% 23.2% 30.9% 35.3% 7.9% 26.4% -7.3% -34.8% 8.8%
Cash Dividends 9,715.00
11,866.00
12,905.00
23,830.00
18,844.00
19,048.00
19,409.00
20,121.00
21,517.00
growth rate 22.1% 8.8% 84.7% -20.9% 1.1% 1.9% 3.7% 6.9%
Cash From OA 21,374.00
22,214.00
25,942.00
31,692.00
38,287.00
48,314.00
41,168.00
44,616.00
46,782.00
51,951.00
55,000.00
growth rate 3.9% 16.8% 22.2% 20.8% 26.2% -14.8% 8.4% 4.9% 11.1% 5.9%
FCF per Share 0.88
1.01
0.90
1.33
1.59
2.04
2.05
1.73
2.06
2.56
2.34
growth rate 14.8% -10.9% 47.8% 19.6% 28.3% 0.5% -15.6% 19.1% 24.3% -8.6%
Sale Purchase of Stock -2,503.00
-2,136.00
-2,717.00
growth rate 0.0% 0.0%
FCF 18,042.00
18,592.00
22,298.00
27,357.00
31,881.00
40,047.00
32,520.00
32,206.00
35,551.00
29,870.00
47,615.00
growth rate 3.1% 19.9% 22.7% 16.5% 25.6% -18.8% -1.0% 10.4% -16.0% 59.4%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 66,346.00
78,026.00
83,572.00
88,806.00
107,927.00
111,780.00
111,696.00
111,831.00
122,021.00
126,946.00
140,800.00
growth rate 17.6% 7.1% 6.3% 21.5% 3.6% -0.1% 0.1% 9.1% 4.0% 10.9%
Op.Income 17,097.00
21,432.00
31,493.00
34,492.00
46,619.00
48,432.00
48,967.00
47,248.00
52,483.00
54,476.00
59,341.00
growth rate 25.4% 46.9% 9.5% 35.2% 3.9% 1.1% -3.5% 11.1% 3.8% 8.9%
IBT 32,539.00
34,096.00
43,483.00
47,798.00
48,680.00
47,615.00
48,553.00
53,130.00
59,080.00
growth rate 4.8% 27.5% 9.9% 1.9% -2.2% 2.0% 9.4% 11.2%
Net Income 17,097.00
21,432.00
25,184.00
26,481.00
34,860.00
37,925.00
38,130.00
38,628.00
38,951.00
42,138.00
47,757.00
growth rate 25.4% 17.5% 5.2% 31.6% 8.8% 0.5% 1.3% 0.8% 8.2% 13.3%
EPS 6.00
7.77
9.35
10.07
13.52
14.96
15.39
15.93
16.38
18.01
20.74
growth rate 29.5% 20.3% 7.7% 34.3% 10.7% 2.9% 3.5% 2.8% 10.0% 15.2%
Gross Profit 53,757.00
64,561.00
69,432.00
74,244.00
91,739.00
94,597.00
94,064.00
94,214.00
101,933.00
106,014.00
117,142.00
growth rate 20.1% 7.5% 6.9% 23.6% 3.1% -0.6% 0.2% 8.2% 4.0% 10.5%
R&D 11,733.00
13,762.00
13,608.00
14,563.00
14,014.00
14,805.00
14,220.00
15,112.00
17,199.00
growth rate 17.3% -1.1% 7.0% -3.8% 5.6% -4.0% 6.3% 13.8%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 14,779.00
15,249.00
14,331.00
19,147.00
18,391.00
growth rate 3.2% -6.0% 33.6% -4.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 30,223.00
35,452.00
46,799.00
44,166.00
46,639.00
growth rate 17.3% 32.0% -5.6% 5.6%
Acct.Payable 7,616.00
8,877.00
8,870.00
6,679.00
14,654.00
growth rate 16.6% -0.1% -24.7% 119.4%
Cur.Assets 77,146.00
91,213.00
85,595.00
86,537.00
102,979.00
growth rate 18.2% -6.2% 1.1% 19.0%
Total Assets 158,095.00
174,084.00
194,508.00
197,136.00
218,928.00
growth rate 10.1% 11.7% 1.4% 11.1%
Cash 24,229.00
29,493.00
10,720.00
13,394.00
22,758.00
growth rate 21.7% -63.7% 24.9% 69.9%
Inventory 18,822.00
18,899.00
19,621.00
20,289.00
21,706.00
growth rate 0.4% 3.8% 3.4% 7.0%
Cur.Liabilities 72,798.00
88,328.00
99,516.00
95,602.00
109,655.00
growth rate 21.3% 12.7% -3.9% 14.7%
Liabilities 92,536.00
107,972.00
123,762.00
130,586.00
144,476.00
growth rate 16.7% 14.6% 5.5% 10.6%
LT Debt 9,654.00
24,084.00
24,178.00
growth rate 149.5% 0.4%
Equity 65,559.00
66,112.00
70,746.00
66,550.00
74,452.00
growth rate 0.8% 7.0% -5.9% 11.9%
Common Shares 462.00
462.00
462.00
462.00
456.00
growth rate 0.0% 0.0% 0.0% -1.3%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 1,709.00
1,175.00
2,049.00
1,520.00
2,435.00
growth rate -31.3% 74.4% -25.8% 60.2%
Cash Dividends 1.00
8,021.00
15,690.00
15,690.00
growth rate 802,000.0% 95.6% 0.0%
Cash From OA 25,255.00
21,507.00
-3,017.00
23,586.00
23,961.00
growth rate -14.8% -100.0% 100.0% 1.6%
FCF 23,546.00
20,332.00
-5,066.00
22,066.00
21,526.00
growth rate -13.7% -100.0% 100.0% -2.5%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 33,041.00
35,622.00
38,333.00
42,031.00
41,265.00
growth rate 7.8% 7.6% 9.7% -1.8%
Op.Income 14,779.00
15,249.00
14,331.00
19,147.00
18,391.00
growth rate 3.2% -6.0% 33.6% -4.0%
IBT 14,917.00
15,112.00
13,113.00
17,919.00
16,795.00
growth rate 1.3% -13.2% 36.7% -6.3%
Net Income 12,123.00
12,119.00
10,892.00
14,210.00
13,318.00
growth rate 0.0% -10.1% 30.5% -6.3%
Gross Profit 27,494.00
29,563.00
32,092.00
35,114.00
35,196.00
growth rate 7.5% 8.6% 9.4% 0.2%
R&D 3,944.00
4,252.00
5,059.00
5,206.00
5,123.00
growth rate 7.8% 19.0% 2.9% -1.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (78.12)

YOY Growth Grade:

C (63.63)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 50.99 7.99 36.01
EPS / Growth 5.7% 2.42 1.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 9.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.4% 5.4% 5.4%
Future PE 2.74 32.63 32.63
Future EPS 2.78 4.11 4.11
Value Price
MOS %
1.88
-90.3%
33.17
71.4%
33.17
71.4%
MOS Price 0.94 16.59 16.59
IRT 7.53 6.51 6.51

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.